Cargando…

Murine Model for Measuring Effects of Humanized-Dosing of Antibiotics on the Gut Microbiome

There is a current need for enhancing our insight in the effects of antimicrobial treatment on the composition of human microbiota. Also, the spontaneous restoration of the microbiota after antimicrobial treatment requires better understanding. This is best addressed in well-defined animal models. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Leopold, Shana R., Abdelraouf, Kamilia, Nicolau, David P., Agresta, Hanako, Johnson, Jethro, Teter, Kathleen, Dunne, Wm Michael, Broadwell, David, van Belkum, Alex, Schechter, Lisa M., Sodergren, Erica J., Weinstock, George M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892246/
https://www.ncbi.nlm.nih.gov/pubmed/35250930
http://dx.doi.org/10.3389/fmicb.2022.813849
_version_ 1784662113068777472
author Leopold, Shana R.
Abdelraouf, Kamilia
Nicolau, David P.
Agresta, Hanako
Johnson, Jethro
Teter, Kathleen
Dunne, Wm Michael
Broadwell, David
van Belkum, Alex
Schechter, Lisa M.
Sodergren, Erica J.
Weinstock, George M.
author_facet Leopold, Shana R.
Abdelraouf, Kamilia
Nicolau, David P.
Agresta, Hanako
Johnson, Jethro
Teter, Kathleen
Dunne, Wm Michael
Broadwell, David
van Belkum, Alex
Schechter, Lisa M.
Sodergren, Erica J.
Weinstock, George M.
author_sort Leopold, Shana R.
collection PubMed
description There is a current need for enhancing our insight in the effects of antimicrobial treatment on the composition of human microbiota. Also, the spontaneous restoration of the microbiota after antimicrobial treatment requires better understanding. This is best addressed in well-defined animal models. We here present a model in which immune-competent or neutropenic mice were administered piperacillin-tazobactam (TZP) according to human treatment schedules. Before, during and after the TZP treatment, fecal specimens were longitudinally collected at established intervals over several weeks. Gut microbial taxonomic distribution and abundance were assessed through culture and molecular means during all periods. Non-targeted metabolomics analyses of stool samples using Quadrupole Time of Flight mass spectrometry (QTOF MS) were also applied to determine if a metabolic fingerprint correlated with antibiotic use, immune status, and microbial abundance. TZP treatment led to a 5–10-fold decrease in bacterial fecal viability counts which were not fully restored during post-antibiotic follow up. Two distinct, relatively uniform and reproducible restoration scenarios of microbiota changes were seen in post TZP-treatment mice. Post-antibiotic flora could consist of predominantly Firmicutes or, alternatively, a more diverse mix of taxa. In general, the pre-treatment microbial communities were not fully restored within the screening periods applied. A new species, closely related to Eubacterium siraeum, Mageeibacillus indolicus, and Saccharofermentans acetigenes, became predominant post-treatment in a significant proportion of mice, identified by 16S rRNA gene sequencing. Principal component analysis of QTOF MS of mouse feces successfully distinguished treated from non-treated mice as well as immunocompetent from neutropenic mice. We observe dynamic but distinct and reproducible responses in the mouse gut microbiota during and after TZP treatment and propose the current murine model as a useful tool for defining the more general post-antibiotic effects in the gastro-intestinal ecosystem where humanized antibiotic dosing may ultimately facilitate extrapolation to humans.
format Online
Article
Text
id pubmed-8892246
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88922462022-03-04 Murine Model for Measuring Effects of Humanized-Dosing of Antibiotics on the Gut Microbiome Leopold, Shana R. Abdelraouf, Kamilia Nicolau, David P. Agresta, Hanako Johnson, Jethro Teter, Kathleen Dunne, Wm Michael Broadwell, David van Belkum, Alex Schechter, Lisa M. Sodergren, Erica J. Weinstock, George M. Front Microbiol Microbiology There is a current need for enhancing our insight in the effects of antimicrobial treatment on the composition of human microbiota. Also, the spontaneous restoration of the microbiota after antimicrobial treatment requires better understanding. This is best addressed in well-defined animal models. We here present a model in which immune-competent or neutropenic mice were administered piperacillin-tazobactam (TZP) according to human treatment schedules. Before, during and after the TZP treatment, fecal specimens were longitudinally collected at established intervals over several weeks. Gut microbial taxonomic distribution and abundance were assessed through culture and molecular means during all periods. Non-targeted metabolomics analyses of stool samples using Quadrupole Time of Flight mass spectrometry (QTOF MS) were also applied to determine if a metabolic fingerprint correlated with antibiotic use, immune status, and microbial abundance. TZP treatment led to a 5–10-fold decrease in bacterial fecal viability counts which were not fully restored during post-antibiotic follow up. Two distinct, relatively uniform and reproducible restoration scenarios of microbiota changes were seen in post TZP-treatment mice. Post-antibiotic flora could consist of predominantly Firmicutes or, alternatively, a more diverse mix of taxa. In general, the pre-treatment microbial communities were not fully restored within the screening periods applied. A new species, closely related to Eubacterium siraeum, Mageeibacillus indolicus, and Saccharofermentans acetigenes, became predominant post-treatment in a significant proportion of mice, identified by 16S rRNA gene sequencing. Principal component analysis of QTOF MS of mouse feces successfully distinguished treated from non-treated mice as well as immunocompetent from neutropenic mice. We observe dynamic but distinct and reproducible responses in the mouse gut microbiota during and after TZP treatment and propose the current murine model as a useful tool for defining the more general post-antibiotic effects in the gastro-intestinal ecosystem where humanized antibiotic dosing may ultimately facilitate extrapolation to humans. Frontiers Media S.A. 2022-02-17 /pmc/articles/PMC8892246/ /pubmed/35250930 http://dx.doi.org/10.3389/fmicb.2022.813849 Text en Copyright © 2022 Leopold, Abdelraouf, Nicolau, Agresta, Johnson, Teter, Dunne, Broadwell, van Belkum, Schechter, Sodergren and Weinstock. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Leopold, Shana R.
Abdelraouf, Kamilia
Nicolau, David P.
Agresta, Hanako
Johnson, Jethro
Teter, Kathleen
Dunne, Wm Michael
Broadwell, David
van Belkum, Alex
Schechter, Lisa M.
Sodergren, Erica J.
Weinstock, George M.
Murine Model for Measuring Effects of Humanized-Dosing of Antibiotics on the Gut Microbiome
title Murine Model for Measuring Effects of Humanized-Dosing of Antibiotics on the Gut Microbiome
title_full Murine Model for Measuring Effects of Humanized-Dosing of Antibiotics on the Gut Microbiome
title_fullStr Murine Model for Measuring Effects of Humanized-Dosing of Antibiotics on the Gut Microbiome
title_full_unstemmed Murine Model for Measuring Effects of Humanized-Dosing of Antibiotics on the Gut Microbiome
title_short Murine Model for Measuring Effects of Humanized-Dosing of Antibiotics on the Gut Microbiome
title_sort murine model for measuring effects of humanized-dosing of antibiotics on the gut microbiome
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892246/
https://www.ncbi.nlm.nih.gov/pubmed/35250930
http://dx.doi.org/10.3389/fmicb.2022.813849
work_keys_str_mv AT leopoldshanar murinemodelformeasuringeffectsofhumanizeddosingofantibioticsonthegutmicrobiome
AT abdelraoufkamilia murinemodelformeasuringeffectsofhumanizeddosingofantibioticsonthegutmicrobiome
AT nicolaudavidp murinemodelformeasuringeffectsofhumanizeddosingofantibioticsonthegutmicrobiome
AT agrestahanako murinemodelformeasuringeffectsofhumanizeddosingofantibioticsonthegutmicrobiome
AT johnsonjethro murinemodelformeasuringeffectsofhumanizeddosingofantibioticsonthegutmicrobiome
AT teterkathleen murinemodelformeasuringeffectsofhumanizeddosingofantibioticsonthegutmicrobiome
AT dunnewmmichael murinemodelformeasuringeffectsofhumanizeddosingofantibioticsonthegutmicrobiome
AT broadwelldavid murinemodelformeasuringeffectsofhumanizeddosingofantibioticsonthegutmicrobiome
AT vanbelkumalex murinemodelformeasuringeffectsofhumanizeddosingofantibioticsonthegutmicrobiome
AT schechterlisam murinemodelformeasuringeffectsofhumanizeddosingofantibioticsonthegutmicrobiome
AT sodergrenericaj murinemodelformeasuringeffectsofhumanizeddosingofantibioticsonthegutmicrobiome
AT weinstockgeorgem murinemodelformeasuringeffectsofhumanizeddosingofantibioticsonthegutmicrobiome